KIRK RANDAL J

Director Kirk Randal J sold 4.77M shares (28.0% of holdings) for $15.8M at $3.30 on 2026-03-30.

Kirk Randal J executed 11 separate sales totaling 4,772,781 shares for $15,750,177.30, reducing his position from 17.04M to 12.26M shares. This represents a substantial 28.0% reduction in holdings in a single trading session. His prior 5 sales at PGEN were executed on 2025-12-22 and all exhibited well-timed patterns with negative 90-day returns (down -21.5% in each case post-sale), reflecting a track record of selling before declines at this ticker. The company operates with significant losses: latest quarter revenue of $1,767,000 against net income of -$146,344,000, and it remains unprofitable on a full-year basis despite reporting annual revenue growth of 146.7%. The director's substantial liquidation following a pattern of historically well-timed PGEN exits merits close attention given the company's challenging profitability profile.

Director Kirk Randal J sells 1,900,036 shares at $4.18 for $7,942,150.48 at PGEN; holdings drop 29.2% in 11 transactions on single day.

Kirk Randal J, a Director at Precigen Inc., executed 11 separate sales totaling 1,900,036 shares for $7,942,150.48 at $4.18 on 2025-12-22, reducing his holdings from 6,498,080 shares to 4,598,044 shares (a -29.2% reduction in his stake). The company is unprofitable with a net income of $-146,344,000.00 and annual revenue growth of -74.1%, creating a context of deteriorating financial performance. His cross-ticker track record shows prior sells had an average 90-day return of +8.2% with a 0% well-timed rate, while his five prior same-ticker sales at PGEN yielded mixed outcomes (only one measurable at 90 days: +13.3%). The multi-tranche structure and substantial dollar magnitude ($7.9M) in a single day warrants tracking against subsequent stock performance to assess whether the timing reflected information asymmetry or coincidence.

Director Kirk Randal J sold 2,966,293 shares (34.8% of holdings) for $12.3M across 3 days at blended avg $4.14, now trading $3.88

Kirk Randal J conducted three separate sales totaling 2,966,293 shares for $12,291,748.11 between November 19–21, 2025, reducing his holdings by 34.8% from 8.52M to 5.55M shares. The sales occurred at declining prices ($4.47, $4.08, $3.83) with a blended average of $4.14, and the stock has since fallen to $3.88 (down 20.8% from its 52-week high). His prior trades at PGEN show a pattern of well-timed sales: the two most recent PGEN sales (September 30 and September 19, 2025) each posted positive 30-day returns (+18.8%, +8.7%), indicating he sold before subsequent declines. Against this backdrop of a 74.1% annual revenue decline, a net income of $-146.3M, and a current unprofitable state, the substantial reduction in a director's ownership stake across a multi-day sequence merits close examination of whether material corporate developments or earnings deterioration prompted the transaction.

Director Kirk Randal J sold 1,809,667 shares of PGEN at $3.41 on 2025-09-30 for $6.2M, reducing stake 11.0% amid -74.1% annual revenue decline and ongoing losses.

Kirk Randal J sold 1,809,667 shares at $3.41 on 2025-09-30, liquidating 11.0% of his PGEN holdings for $6,170,964.47 while retaining 14.60M shares. This sale follows two other PGEN sells in mid-September and occurs against a backdrop of severe operational deterioration: the company reported -74.1% annual revenue decline and a full-year net loss of -$26,642,000.00, with latest quarterly revenue at only $1,767,000.00. The stock has declined 30.9% from its 52-week high and 27.0% over the past 30 days. Across his prior PGEN trades, the insider showed 2 of 3 measurable outcomes well-timed at the 90-day mark—including his buy on 2024-08-09 returning 11.9% and his buy on 2023-12-28 returning 2.8%—but his cross-ticker track record shows 33.33% 90-day win rate with average 90-day return of -23.7% on prior buys. The confluence of severe revenue contraction, persistent unprofitability, repeated September sales, and stock price deterioration suggests a director reassessment of the company's near-term trajectory.

Director Kirk Randal J sells 5,000,252 shares at blended $3.73 for $18.7M; stake reduced 37.0% to 8.52M shares

Kirk Randal J executed two separate sales totaling 5,000,252 shares on 2025-09-18 and 2025-09-19, reducing his stake by 37.0% from 13.52M to 8.52M shares and raising $18,653,532.16. The sales occurred near the 52-week high (current price $3.75 is -21.2% from $4.76 peak), within the stock's 30-day +16.8% and 90-day +158.6% rally. PGEN faces severe operational headwinds: revenue contracted 74.1% year-over-year to $1,767,000 in the latest quarter, the company posted a $26,642,000 net loss, and remains unprofitable on a full-year basis despite a $1.1B market cap—a significant valuation disconnect. Director's prior trades at PGEN show mixed timing outcomes (2 of 5 prior buys yielded positive 90-day returns), though his cross-ticker track record is notably weak (33.33% win rate, -23.7% average 90-day return on buys). This large, material reduction in directorial stake amid a period of relative stock strength and deteriorating fundamentals warrants investor attention.

Director Kirk Randal J purchases 23,529,411 shares of PGEN at $0.85 for $19,999,999.35; stock now trading at $1.09, off 42.0% from 52-week high.

Kirk Randal J, a director at Precigen, deployed approximately $20.0M to purchase 23,529,411 shares at $0.85 on August 9, 2024, increasing his holdings by 57.4%. The transaction size and magnitude are substantial, yet context raises caution: the current price of $1.09 is -42.0% from the 52-week high and down 32.3% over the past 30 days. His same-ticker buy history at PGEN shows 1 well-timed outcome out of 5 prior purchases, with four of the five generating negative 90-day returns ranging from -33.1% to -41.8%. The company itself faces significant headwinds: quarterly revenue contracted to $1.8M (with annual revenue growth of -74.1%), and the firm posted a $-23.7M net loss in its most recent full fiscal year. This large insider accumulation occurs against deteriorating price momentum and fundamental weakness, warranting investor scrutiny of what has motivated such a substantial commitment at this juncture.